ScholarLens Back to search
2019•Journal watchRequires access

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

Deanna Saylor, Mhs

Open publisher page 0 citations

Abstract

Despite off-label treatment with immunosuppressive regimens such as azathioprine and rituximab, many individuals with neuromyelitis optica spectrum

About this research paper

What this paper is about

Despite off-label treatment with immunosuppressive regimens such as azathioprine and rituximab, many individuals with neuromyelitis optica spectrum

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Despite off-label treatment with immunosuppressive regimens such as azathioprine and rituximab, many individuals with neuromyelitis optica spectrum

Key concepts: Neuromyelitis optica, Eculizumab, Spectrum disorder, Medicine, Aquaporin 4, Dermatology, Immunology, Multiple sclerosis

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder — Research Paper | ScholarLens